Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.40 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | ERN1 | O75460 | 5/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492569 | 0.90 | ALDH1A1 (0.46) | KDM4ELMNAGAAMAPTALDH1A1 | |
| SCHEMBL29955060 | 0.80 | ALDH1A1 (0.56) | KDM4ELMNAGAAMAPTALDH1A1 | |
| SCHEMBL5486093 | 0.77 | PRKDC (0.45) | KDM4ELMNAMAPTALDH1A1ERN1 | |
| SCHEMBL6545157 | 0.77 | ALDH1A1 (0.55) | KDM4ELMNAMAPTALDH1A1ERN1 | |
| SCHEMBL21000852 | 0.73 | KDM4E (0.60) | KDM4EGAAMAPTALDH1A1PDE4D | |
| SCHEMBL5490878 | 0.72 | PRKDC (0.46) | KDM4ELMNAGAAMAPTALDH1A1 | |
| SCHEMBL2761533 | 0.72 | ALDH1A1 (0.74) | KDM4ELMNAMAPTALDH1A1PDE4D | |
| SCHEMBL2474418 | 0.71 | ERN1 (0.57) | KDM4ELMNAGAAALDH1A1ERN1 | |
| SCHEMBL15618978 | 0.71 | ERN1 (0.53) | KDM4ELMNAGAAMAPTALDH1A1 | |
| SCHEMBL5489380 | 0.70 | PRKDC (0.47) | KDM4ELMNAMAPTALDH1A1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | KDM4E 2914/4885LMNA 1410/4885GAA 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.